**Review Form 3**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Journal Name: |  | [**Journal of Scientific Research and Reports**](https://journaljsrr.com/index.php/JSRR) | |  |
|  |  |  |  |  |
| Manuscript Number: |  | **Ms\_JSRR\_133742** | |  |
|  |  |  |  |  |
| Title of the Manuscript: |  | **Establishment of In-Vitro Cell Cultures Using Patient-Derived Ascitic or Pleural Fluid from Cancer Patients.** | |  |
|  |  |  |
|  |  |  |  |  |
| Type of the Article |  |  |  |  |
|  |  |  |  |  |

**Review Form 3**

**PART 1: Comments**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  | **Reviewer’s comment** | |  | **Author’s Feedback** *(Please correct the manuscript and highlight that part* |
|  |  |  |  | **Artificial Intelligence (AI) generated or assisted review comments are strictly prohibited during peer** | |  | *in the manuscript. It is mandatory that authors should write his/her feedback* |
|  |  |  |  | **review.** |  |  | *here)* |
|  |  |  |  | | |  |  |
|  | **Please write a few sentences regarding the importance** | | Authors established cell cultures in-vitro using patient-derived ascitic or pleural fluid from cancer | | |  |  |
|  | **of this manuscript for the scientific community. A** | | patients, it valuable and is helpful to carry out further research on cell culture and cancer biology to | | |  | Yes, we have tried to provide valuable insights into the potential of using ascitic and pleural fluid samples from cancer patients for primary cell culture in cancer research. |
|  | **minimum of 3-4 sentences may be required for this** | | identify drug action mechanisms, drug resistance, radiosensitivity evaluation, etc.But, | | |  |  |
|  | **part.** | | 1.There are many grammatical mistakes. | | |  |  |
|  |  |  | 1. It was helpful that Authors should display the baseline patient characteristics, such as cancer type, stage, as well as the characteristics of ascitic or pleural fluid, such as the color of of ascitic or pleural fluid. 2. How about the inclusion and exclusion criteria, give the explanation for why only 12/20 samples succeeded. 3. Authors should give the detail information on culture conditions , such as CO₂ concentration, medium composition ratios, which is compromising reproducibility. 4. In the section of Discussion , authors should give detail discussion on low proliferation rates in some samples,such as possibly due to prior treatment or tumor heterogeneity, as well as the study limitations. | | |  |  |
|  | **Is the title of the article suitable?** | | Yes | | |  | Thank you. |
|  | **(If not please suggest an alternative title)** | |  | | |  |  |
|  |  |  |  | | |  |  |
|  | **Is the abstract of the article comprehensive? Do you** | | No, the abstract lacks quantitative data, such as success rate: 12/20 samples, 60%. | | |  | We have added it. |
|  | **suggest the addition (or deletion) of some points in this** | |  | | |  |  |
|  | **section? Please write your suggestions here.** | |  | | |  |  |
|  |  |  |  | | |  |  |
|  | **Is the manuscript scientifically, correct? Please write** | | No, Authors should display the baseline patient characteristics, such as cancer type, stage, as well as the | | |  | We have mentioned all the characteristics of twelve patients through a table and results. We have added all the detailed observations in the discussion section as well to compare the observations. We restructured the ‘Results’ and ‘Discussion’ sections to meet your criteria. We added the cancer types in the table now. Culture conditions and other details have been mentioned in the methodology section.  We have mentioned the colour, characteristics of fluids, details of culture conditions. |
|  | **here.** | | characteristics of ascitic or pleural fluid, such as the color of of ascitic or pleural fluid. | | |  |  |
|  |  |  | Authors should give the detail information on culture conditions , such as CO₂ concentration, medium composition ratios, which is compromising reproducibility.In the section of Discussion , authors should give detail discussion on low proliferation rates in some samples,such as possibly due to prior treatment or tumor heterogeneity, as well as the study limitations. | | |  |  |
|  | **Are the references sufficient and recent? If you have** | | Yes | | |  | Thank you. |
|  | **suggestions of additional references, please mention** | |  | | |  |  |
|  | **them in the review form.** | |  | | |  |  |
|  |  |  |  | | |  |  |
|  | **Is the language/English quality of the article suitable** | | There are many grammatical mistakes, and Reference formatting is inconsistent. | | |  | We have rechecked and corrected it in the revised manuscript. |
|  | **for scholarly communications?** | |  | | |  |  |
|  |  | |  | | |  |  |
|  | **Optional/General** comments | |  | | |  |  |
|  |  |  |  |  | Actually, this paper is novelty in part,  But insufficient and English writing here is poor. |  | We tried to restructure and revise the sections as per three reviewers’ comments and also revised the grammar. |

|  |  |  |
| --- | --- | --- |
| **PART 2:** | | |
|  | **Reviewer’s comment** | **Author’s comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?** | *(If yes, Kindly please write down the ethical issues here in details)* | We had taken necessary ethical permission from the ethical committee of Chittaranjan National Cancer Institute. Necessary consent to use patient samples for clinical research purpose had been taken from patients or their family members. This study began after receiving approval from the ethical committee of CNCI. |